201 related articles for article (PubMed ID: 1558402)
21. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
Iemura K; Moriya Y
Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
23. Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
Filella X; Molina R; Mengual PJ; Jo J; Ballesta AM
J Nucl Biol Med (1991); 1991; 35(3):158-61. PubMed ID: 1816871
[TBL] [Abstract][Full Text] [Related]
24. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection.
Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E
J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.
Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T
Am J Gastroenterol; 1996 Jan; 91(1):49-53. PubMed ID: 8561143
[TBL] [Abstract][Full Text] [Related]
27. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
[TBL] [Abstract][Full Text] [Related]
29. [Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment].
Ychou M; Tuszinski T; Pignon JP; Bidart JM; Bellet D; Bohuon C; Rougier P
Gastroenterol Clin Biol; 1992; 16(11):848-52. PubMed ID: 1483553
[TBL] [Abstract][Full Text] [Related]
30. [Histopathological and immunohistochemical studies on the elevation mechanism of cancer associated antigens, CEA and CA19-9, in gastric cancer patients].
Tabuchi Y; Deguchi H; Saitoh Y
Nihon Geka Gakkai Zasshi; 1988 Aug; 89(8):1181-91. PubMed ID: 3185486
[TBL] [Abstract][Full Text] [Related]
31. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
32. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
[TBL] [Abstract][Full Text] [Related]
33. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.
Liang Y; Wang W; Fang C; Raj SS; Hu WM; Li QW; Zhou ZW
Oncotarget; 2016 Aug; 7(31):49565-49573. PubMed ID: 27385101
[TBL] [Abstract][Full Text] [Related]
35. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer.
Ucar E; Semerci E; Ustun H; Yetim T; Huzmeli C; Gullu M
Adv Ther; 2008 Oct; 25(10):1075-84. PubMed ID: 18821070
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K; Ishikawa H
Anticancer Res; 2002; 22(1A):451-8. PubMed ID: 12017332
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Emoto S; Ishigami H; Yamashita H; Yamaguchi H; Kaisaki S; Kitayama J
Gastric Cancer; 2012 Apr; 15(2):154-61. PubMed ID: 21892754
[TBL] [Abstract][Full Text] [Related]
40. [The role of tumor markers in diagnosing metastases of gastric cancer: preoperative diagnostics (part I)].
Kurygin AA; Maĭstrenko NA; Khrykov GN; Beliak NP
Vestn Khir Im I I Grek; 2009; 168(4):16-9. PubMed ID: 19947409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
